Rani Therapeutics Holdings, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 7.1 million compared to USD 8.79 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.35 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.83 USD | +0.26% |
|
+2.14% | +15.06% |
24/06 | Rani Therapeutics Partners With ProGen for Oral Obesity Treatment Development; Shares Rise | MT |
24/06 | Transcript : Rani Therapeutics Holdings, Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.06% | 10Cr | |
+17.05% | 12TCr | |
+18.45% | 11TCr | |
+19.71% | 2.57TCr | |
-25.24% | 1.9TCr | |
-20.21% | 1.58TCr | |
-19.46% | 1.53TCr | |
-47.37% | 1.49TCr | |
+62.27% | 1.48TCr | |
+5.33% | 1.41TCr |
- Stock Market
- Equities
- RANI Stock
- News Rani Therapeutics Holdings, Inc.
- Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023